high-risk – Talk Bio

FDA Approves Darzalex Faspro for High-Risk Smoldering Multiple Myeloma

4 weeks ago talkbio0Tagged Approved, AQUILA study, daratumumab, Darzalex Faspro, Early Intervention (Education), high-risk, Progression-Free Survival, Smoldering myeloma, United States Food and Drug Administration

FDA approval; Darzalex Faspro; high-risk smoldering multiple myeloma; AQUILA study; early intervention; progression-free survival; daratumumab; hyaluronidase-fihj

FDA Approves Moderna’s Next-Generation Covid Vaccine With Limited Use for Most Healthy People

6 months ago talkbio0Tagged Approved, COVID19 (disease), Elderly (population group), high-risk, Moderna, next-generation Covid vaccine, Omicron, Omicron JN.1, restrictions, Spikevax, United States Food and Drug Administration, Vaccines, Variant

Moderna; FDA approval; mNexspike; next-generation Covid vaccine; vaccine restrictions; Covid-19; Spikevax; elderly; high-risk medical conditions; Omicron JN.1 variant

AstraZeneca opens the door to Imfinzi expansion with trial win in high-risk bladder cancer patients

7 months ago talkbio0Tagged Clinical Trials, expansion, high-risk, Imfinzi, Malignant neoplasm of urinary bladder

Imfinzi, Clinical Trials, high-risk, expansion, Malignant neoplasm of urinary bladder

KEYTRUDA (Pembrolizumab) Plus Chemoradiotherapy Reduces Mortality Risk by 33% in High-Risk Locally Advanced Cervical Cancer

1 year ago talkbio0Tagged Chemoradiotherapy, Congress, Congress (U.S. Legislature), high-risk, Keytruda, Locally, Malignant tumor of cervix, Overall Survival, pembrolizumab

KEYTRUDA (pembrolizumab), Chemoradiotherapy (CRT), High-risk locally advanced cervical cancer, Overall survival (OS), European Society for Medical Oncology (ESMO) Congress 2024